These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 37448966)

  • 21. Serum Bactericidal Activity Levels Monitor to Guide Intravenous Dalbavancin Chronic Suppressive Therapy of Inoperable Staphylococcal Prosthetic Valve Endocarditis: A Case Report.
    Spaziante M; Franchi C; Taliani G; D'Avolio A; Pietropaolo V; Biliotti E; Esvan R; Venditti M
    Open Forum Infect Dis; 2019 Nov; 6(11):ofz427. PubMed ID: 31737736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous suppressive antibiotic therapy for bone and joint infections: safety and outcome in a cohort of 10 patients.
    Pouderoux C; Becker A; Goutelle S; Lustig S; Triffault-Fillit C; Daoud F; Fessy MH; Cohen S; Laurent F; Chidiac C; Valour F; Ferry T;
    J Antimicrob Chemother; 2019 Jul; 74(7):2060-2064. PubMed ID: 31220276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful long-term antibiotic suppressive therapy in a case of prosthetic valve endocarditis and a case of extensive aortic and subclavian graft infection.
    Lechner AM; Pretsch I; Hoppe U; Seitelberger R; Dinges C
    Infection; 2020 Feb; 48(1):133-136. PubMed ID: 31123929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
    Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
    Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Life-long antimicrobial therapy: where is the evidence?
    Lau JSY; Korman TM; Woolley I
    J Antimicrob Chemother; 2018 Oct; 73(10):2601-2612. PubMed ID: 29873746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.
    Werth BJ; Jain R; Hahn A; Cummings L; Weaver T; Waalkes A; Sengupta D; Salipante SJ; Rakita RM; Butler-Wu SM
    Clin Microbiol Infect; 2018 Apr; 24(4):429.e1-429.e5. PubMed ID: 28782651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Antibiotic Suppressive Therapy in Patients with a Prosthetic Joint Infection.
    Wouthuyzen-Bakker M; Nijman JM; Kampinga GA; van Assen S; Jutte PC
    J Bone Jt Infect; 2017; 2(2):77-83. PubMed ID: 28529867
    [No Abstract]   [Full Text] [Related]  

  • 29. Prolonged suppressive antibiotic therapy for prosthetic joint infection in the elderly: a national multicentre cohort study.
    Prendki V; Ferry T; Sergent P; Oziol E; Forestier E; Fraisse T; Tounes S; Ansart S; Gaillat J; Bayle S; Ruyer O; Borlot F; Le Falher G; Simorre B; Dauchy FA; Greffe S; Bauer T; Bell EN; Martha B; Martinot M; Froidure M; Buisson M; Waldner A; Lemaire X; Bosseray A; Maillet M; Charvet V; Barrelet A; Wyplosz B; Noaillon M; Denes E; Beretti E; Berlioz-Thibal M; Meyssonnier V; Fourniols E; Tliba L; Eden A; Jean M; Arvieux C; Guignery-Kadri K; Ronde-Oustau C; Hansmann Y; Belkacem A; Bouchand F; Gavazzi G; Herrmann F; Stirnemann J; Dinh A
    Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1577-1585. PubMed ID: 28378243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).
    Ariza J; Cobo J; Baraia-Etxaburu J; Benito N; Bori G; Cabo J; Corona P; Esteban J; Horcajada JP; Lora-Tamayo J; Murillo O; Palomino J; Parra J; Pigrau C; Del Pozo JL; Riera M; Rodríguez D; Sánchez-Somolinos M; Soriano A; Del Toro MD; de la Torre B; ;
    Enferm Infecc Microbiol Clin; 2017 Mar; 35(3):189-195. PubMed ID: 28215487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.
    Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J
    Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of patients over 80 years of age on prolonged suppressive antibiotic therapy for at least 6 months for prosthetic joint infection.
    Prendki V; Zeller V; Passeron D; Desplaces N; Mamoudy P; Stirnemann J; Marmor S; Ziza JM
    Int J Infect Dis; 2014 Dec; 29():184-9. PubMed ID: 25447723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
    Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
    N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppressive therapy using azithromycin in 2 rare cases of recurrent staphylococcal infections.
    Grobost V; Rigal E; Pavier Y; Vidal M; Mrozek N; Beytout J; Laurichesse H; Lesens O
    Diagn Microbiol Infect Dis; 2014 May; 79(1):90-2. PubMed ID: 24629578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prosthetic joint infection: diagnosis and management.
    Cobo J; Del Pozo JL
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):787-802. PubMed ID: 21905787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One hundred and twelve infected arthroplasties treated with 'DAIR' (debridement, antibiotics and implant retention): antibiotic duration and outcome.
    Byren I; Bejon P; Atkins BL; Angus B; Masters S; McLardy-Smith P; Gundle R; Berendt A
    J Antimicrob Chemother; 2009 Jun; 63(6):1264-71. PubMed ID: 19336454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030.
    Kurtz S; Ong K; Lau E; Mowat F; Halpern M
    J Bone Joint Surg Am; 2007 Apr; 89(4):780-5. PubMed ID: 17403800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prosthetic-joint infections.
    Zimmerli W; Trampuz A; Ochsner PE
    N Engl J Med; 2004 Oct; 351(16):1645-54. PubMed ID: 15483283
    [No Abstract]   [Full Text] [Related]  

  • 39. [Long-term antibiotic suppressive therapy for an infected thoracic aorta graft].
    Berdal JE; Steinbakk M
    Tidsskr Nor Laegeforen; 2003 Aug; 123(16):2260-2. PubMed ID: 14508548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term suppression of infection in total joint arthroplasty.
    Rao N; Crossett LS; Sinha RK; Le Frock JL
    Clin Orthop Relat Res; 2003 Sep; (414):55-60. PubMed ID: 12966277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.